NCT05216666 The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty
| NCT ID | NCT05216666 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sahlgrenska University Hospital |
| Condition | Hip Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 580 participants |
| Start Date | 2022-05-11 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 580 participants in total. It began in 2022-05-11 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.
Eligibility Criteria
Inclusion Criteria: * Primary unilateral osteoarthritis of the hip scheduled for total hip arthroplasty. * Ability to understand and write swedish. Exclusion Criteria: * Impaired funktion of the contralateral hip or knees causing limping. * Neuromuscular diseases * Postoperative leg length discrepancy excceding 1 cm * Postoperative discrepancy in femoral offset exceeding 25% of the femoral offset of the contralateral hip.
Contact & Investigator
Georgios Tsikandylakis, MD PhD
PRINCIPAL INVESTIGATOR
Sahlgrenska University Hospital
Frequently Asked Questions
Who can join the NCT05216666 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Hip Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05216666 currently recruiting?
Yes, NCT05216666 is actively recruiting participants. Contact the research team at tsikandylakis@gmail.com for enrollment information.
Where is the NCT05216666 trial being conducted?
This trial is being conducted at Mölndal, Sweden.
Who is sponsoring the NCT05216666 clinical trial?
NCT05216666 is sponsored by Sahlgrenska University Hospital. The principal investigator is Georgios Tsikandylakis, MD PhD at Sahlgrenska University Hospital. The trial plans to enroll 580 participants.